Cargando…
Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
The onset of brain metastases (BM) is a major turning point during advanced breast cancer (ABC) evolution, with only few treatment options when local therapies have failed. The therapeutic effect of eribulin, a wildly used drug in the treatment of ABC, remains unclear in this setting. Patients and M...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003126/ https://www.ncbi.nlm.nih.gov/pubmed/33803894 http://dx.doi.org/10.3390/jcm10061272 |
_version_ | 1783671616588218368 |
---|---|
author | Sabatier, Renaud Martin, Johan Vicier, Cécile Guérin, Mathilde Monneur, Audrey Provansal, Magali Tassy, Louis Tarpin, Carole Extra, Jean-Marc Viret, Frédéric Goncalves, Anthony |
author_facet | Sabatier, Renaud Martin, Johan Vicier, Cécile Guérin, Mathilde Monneur, Audrey Provansal, Magali Tassy, Louis Tarpin, Carole Extra, Jean-Marc Viret, Frédéric Goncalves, Anthony |
author_sort | Sabatier, Renaud |
collection | PubMed |
description | The onset of brain metastases (BM) is a major turning point during advanced breast cancer (ABC) evolution, with only few treatment options when local therapies have failed. The therapeutic effect of eribulin, a wildly used drug in the treatment of ABC, remains unclear in this setting. Patients and Methods: We performed a retrospective observational study to assess eribulin efficacy in patients with ABC who displayed BM at time of eribulin initiation. We collected data from the medical files of all ABC patients who received eribulin at our institution from 2012 until 2020. Our main endpoint was the central nervous system (CNS) progression-free survival. (CNS-PFS). Other evaluation criteria were extra-cranial progression free survival (PFS) and overall survival (OS). Results: Twenty patients with BM monitoring data available were selected out of the 549 who received eribulin during the inclusion period. Fifteen patients (75%) had BM progressive as the best response, three patients (15%) had disease stabilization for more than 6 months and only one patient had a partial response according to RECIST 1.1 criteria. Median CNS-PFS was 3.39 months (95CI (3.02–3.76)). Cox univariate analysis identified molecular subtype as the only prognostic parameter in our cohort, with patients with hormone-receptor positive tumors less likely to experience CNS progression than those with triple-negative MBC (HR = 0.23 (95CI = 0.07–0.80), p = 0.021). Median extra-cranial PFS was 2.67 months (95CI (2.33–3.01)). Median OS was 7.68 months (95CI (0–17.41)). Conclusion: Eribulin seems to have only a limited impact on BM evolution. Hormone receptors expression may identify a subset of patients with better BM control. |
format | Online Article Text |
id | pubmed-8003126 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80031262021-03-28 Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer Sabatier, Renaud Martin, Johan Vicier, Cécile Guérin, Mathilde Monneur, Audrey Provansal, Magali Tassy, Louis Tarpin, Carole Extra, Jean-Marc Viret, Frédéric Goncalves, Anthony J Clin Med Article The onset of brain metastases (BM) is a major turning point during advanced breast cancer (ABC) evolution, with only few treatment options when local therapies have failed. The therapeutic effect of eribulin, a wildly used drug in the treatment of ABC, remains unclear in this setting. Patients and Methods: We performed a retrospective observational study to assess eribulin efficacy in patients with ABC who displayed BM at time of eribulin initiation. We collected data from the medical files of all ABC patients who received eribulin at our institution from 2012 until 2020. Our main endpoint was the central nervous system (CNS) progression-free survival. (CNS-PFS). Other evaluation criteria were extra-cranial progression free survival (PFS) and overall survival (OS). Results: Twenty patients with BM monitoring data available were selected out of the 549 who received eribulin during the inclusion period. Fifteen patients (75%) had BM progressive as the best response, three patients (15%) had disease stabilization for more than 6 months and only one patient had a partial response according to RECIST 1.1 criteria. Median CNS-PFS was 3.39 months (95CI (3.02–3.76)). Cox univariate analysis identified molecular subtype as the only prognostic parameter in our cohort, with patients with hormone-receptor positive tumors less likely to experience CNS progression than those with triple-negative MBC (HR = 0.23 (95CI = 0.07–0.80), p = 0.021). Median extra-cranial PFS was 2.67 months (95CI (2.33–3.01)). Median OS was 7.68 months (95CI (0–17.41)). Conclusion: Eribulin seems to have only a limited impact on BM evolution. Hormone receptors expression may identify a subset of patients with better BM control. MDPI 2021-03-18 /pmc/articles/PMC8003126/ /pubmed/33803894 http://dx.doi.org/10.3390/jcm10061272 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sabatier, Renaud Martin, Johan Vicier, Cécile Guérin, Mathilde Monneur, Audrey Provansal, Magali Tassy, Louis Tarpin, Carole Extra, Jean-Marc Viret, Frédéric Goncalves, Anthony Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer |
title | Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer |
title_full | Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer |
title_fullStr | Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer |
title_full_unstemmed | Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer |
title_short | Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer |
title_sort | eribulin efficacy on brain metastases in heavily pretreated patients with metastatic breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003126/ https://www.ncbi.nlm.nih.gov/pubmed/33803894 http://dx.doi.org/10.3390/jcm10061272 |
work_keys_str_mv | AT sabatierrenaud eribulinefficacyonbrainmetastasesinheavilypretreatedpatientswithmetastaticbreastcancer AT martinjohan eribulinefficacyonbrainmetastasesinheavilypretreatedpatientswithmetastaticbreastcancer AT viciercecile eribulinefficacyonbrainmetastasesinheavilypretreatedpatientswithmetastaticbreastcancer AT guerinmathilde eribulinefficacyonbrainmetastasesinheavilypretreatedpatientswithmetastaticbreastcancer AT monneuraudrey eribulinefficacyonbrainmetastasesinheavilypretreatedpatientswithmetastaticbreastcancer AT provansalmagali eribulinefficacyonbrainmetastasesinheavilypretreatedpatientswithmetastaticbreastcancer AT tassylouis eribulinefficacyonbrainmetastasesinheavilypretreatedpatientswithmetastaticbreastcancer AT tarpincarole eribulinefficacyonbrainmetastasesinheavilypretreatedpatientswithmetastaticbreastcancer AT extrajeanmarc eribulinefficacyonbrainmetastasesinheavilypretreatedpatientswithmetastaticbreastcancer AT viretfrederic eribulinefficacyonbrainmetastasesinheavilypretreatedpatientswithmetastaticbreastcancer AT goncalvesanthony eribulinefficacyonbrainmetastasesinheavilypretreatedpatientswithmetastaticbreastcancer |